4 ms·
How do you see the risk of the most greedy company bidding the most to get privileged access to the data, and coming up with a cure that out-prices you or your
by hrktb 7y ago
How do you see the risk of the most greedy company bidding the most to get privileged access to the data, and coming up with a cure that out-prices you or your family if you ever end up hit by the disease ?
For me this is the simulation that gives me pause. I also guess that research might not just happen on itself, but can't help to wonder what better ways they could be to avoid getting cornered at the end.
- drusepth 7y ago>How do you see the risk of the most greedy company bidding the most to get privileged access to the data, and coming up with a cure that out-prices you or your family if you ever end up hit by the disease? Is that preferable to an alternative where no company can bid on such data, and therefore a cure either never exists or is delayed N years (where N is probably significant)? Consider also that all medicine often starts prohibitively expensive to offset R&D, and predictably lowers in cost over time.
- gowld 7y ago"Mylan now offers the authorized generic for Epipen for roughly $150 to $350 for a two-pack" (which expires after 1 year.)